Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Lung Inflammation Clear all
Completed No phase listed Observational

Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure

NCT03225807
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS, Respiratory Distress Syndrome, Acute, Respiratory Insufficiency, Respiratory Distress Syndrome, Shock Lung, Severe Acute Respiratory Syndrome
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ascorbic Acid (Vitamin C) Infusion in Human Sepsis

NCT01434121
View directory record Official record
Conditions
Sepsis, Septic Shock, Hypotension, Acute Lung Injury
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Immulina TM Supplements With PASC Patients

NCT05524532
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
8
States / cities
Honolulu, Hawaii • Baton Rouge, Louisiana • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 29, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 29, 2026, 3:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 29, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Early Insulin and Development of ARDS

NCT00605696
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 29, 2026, 3:52 PM EDT
Completed No phase listed Observational

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

NCT04706533
View directory record Official record
Conditions
Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
Interventions
Biomarkers of inflammation
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 29, 2026, 3:52 PM EDT
Completed No phase listed Observational

Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury

NCT00980915
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 29, 2026, 3:52 PM EDT
Terminated Phase 1 Interventional Results available

Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

NCT04870125
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Sepsis
Interventions
Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 29, 2026, 3:52 PM EDT
Completed No phase listed Observational

Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome

NCT02265198
View directory record Official record
Conditions
Pulmonary Contusion, Respiratory Failure, ARDS
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 29, 2026, 3:52 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air

NCT05680831
View directory record Official record
Conditions
Lung Injury, Acute, Symptoms and Signs, Neutrophilia Acute
Interventions
0.070 ppm ozone concentration, Clean air (0.0 ppm ozone)
Biological
Lead sponsor
Martin W. Case
Federal
Eligibility
18 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 29, 2026, 3:52 PM EDT
Terminated Phase 3 Interventional Results available

Statins for Acutely Injured Lungs From Sepsis

NCT00979121
View directory record Official record
Conditions
Sepsis, Acute Lung Injury
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
40
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

NCT03202394
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
BIO-11006, Placebo
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

NCT04291508
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions
Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Not applicable Interventional

Evaluating Artificial Intelligence-Based Clinical Decision Support for Sepsis and ARDS

NCT07025096
View directory record Official record
Conditions
Sepsis, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Artifical Intelligence-Generated Treatment Recommendations
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 29, 2026, 3:52 PM EDT
Completed No phase listed Observational

Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis

NCT01725061
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 29, 2026, 3:52 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Recovery of Physical Function After Critical Illness In Older Adults

NCT07225257
View directory record Official record
Conditions
Sepsis, Acute Lung Injury(ALI)
Interventions
Not listed
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 29, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional Results available

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

NCT04365257
View directory record Official record
Conditions
COVID-19
Interventions
Prazosin, Standard of care
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 29, 2026, 3:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program

NCT03296280
View directory record Official record
Conditions
Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis, Cellulitis, Abdominal Aortic Aneurysm, Acute Cholecystitis, Peritoneal Free Fluid, Hydronephrosis, Pleural Effusion, Urinary Retention
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 29, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

NCT02106975
View directory record Official record
Conditions
Acute Lung Injury, Sepsis
Interventions
Ascorbic Acid, Placebo: 5% Dextrose in water
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Lexington, Kentucky • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 29, 2026, 3:52 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Effects of Bronchial Segmental Endotoxin Instillation in Humans

NCT02392442
View directory record Official record
Conditions
Acute Lung Inflammation
Interventions
Saline, Endotoxin
Other · Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 3:52 PM EDT
Completed No phase listed Observational

PET Imaging in Patients at Risk for Acute Lung Injury

NCT01486342
View directory record Official record
Conditions
Acute Lung Injury, Early Pulmonary Neutrophilic Inflammation
Interventions
PET-CT scan
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 29, 2026, 3:52 PM EDT